About BioXell
BioXell is a company based in Segrate (Italy) founded in 2002 was acquired by Cosmo Pharmaceuticals in November 2009.. BioXell has raised $79.28 million across 5 funding rounds from investors including Cosmo Pharmaceuticals, Life Sciences Partners and BB Biotech. BioXell operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Segrate, Italy
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$79.28 M (USD)
in 5 rounds
-
Latest Funding Round
$12.57 M (USD), Series C
Mar 15, 2006
-
Investors
Cosmo Pharmaceuticals
& 8 more
-
Employee Count
Employee Count
-
Acquired by
Cosmo Pharmaceuticals
(Nov 18, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of BioXell
BioXell has successfully raised a total of $79.28M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $12.57 million completed in March 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $12.6M
-
First Round
First Round
(26 Mar 2002)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2006 | Amount | Series C - BioXell | Valuation |
investors |
|
| Oct, 2005 | Amount | Grant - BioXell | Valuation |
investors |
|
| Oct, 2005 | Amount | Series C - BioXell | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in BioXell
BioXell has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Cosmo Pharmaceuticals, Life Sciences Partners and BB Biotech. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Founded Year | Domain | Location | |
|
Venture capital investments in technology startups and entrepreneurs.
|
Founded Year | Domain | Location | |
|
Private equity investments in life sciences businesses are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by BioXell
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - BioXell
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Bioxell Comparisons
Competitors of BioXell
BioXell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Bioxell
Frequently Asked Questions about BioXell
When was BioXell founded?
BioXell was founded in 2002.
Where is BioXell located?
BioXell is headquartered in Segrate, Italy. It is registered at Segrate, Lombardy, Italy.
Is BioXell a funded company?
BioXell is a funded company, having raised a total of $79.28M across 5 funding rounds to date. The company's 1st funding round was a Grant of $8.73M, raised on Mar 26, 2002.
What does BioXell do?
BioXell was an Italian, clinical stage biopharma developing small molecule and antibody therapeutics for chronic inflammatory and autoimmune diseases. The company was founded with 22M funding as a spinout of Roche Milano Ricerche, a leading biomedical research institute. BioXell worked on urology, inflammation, pain, and other related disorders. The company was focusing on the development of monoclonal antibody BXL1H5 for the treatment of chronic pain- This was later licensed to Novo Nordisk. Its lead compound, Elocalcitol, a VD3 analog, has completed a Phase IIb clinical trial in benign prostatic hyperplasia and a Phase IIb clinical trial in overactive bladder. The company is also developing BXL746, a vitamin D analog under Phase I clinical trail, for the prevention of post-surgical adhesion formation. BioXell had a license and collaboration agreement with Merck for the development of therapeutic and diagnostic products related to triggering receptors expressed on myeloid cells. The company was acquired by Cosmo Pharma in Nov 2009 for 41M.
Who are the top competitors of BioXell?
BioXell's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Who are BioXell's investors?
BioXell has 9 investors. Key investors include Cosmo Pharmaceuticals, Life Sciences Partners, BB Biotech, Index Ventures, and TVM Capital Life Science.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.